Initiator Pharma A/S (SE:INIT)

:INIT

INIT

Initiator Pharma A/S

RESEARCH TOOLSreports

Want to see SE:INIT full AI Analyst Report?

Initiator Pharma A/S (INIT) Price & Analysis

0 Followers

INIT Stock Chart & Stats

kr3.04

-kr0.20(-3.17%)

At close: Mar 06 4:00 PM EST

kr3.04

-kr0.20(-3.17%)

Day’s Range― - ―

52-Week Rangekr2.56 - kr4.17

Previous CloseN/A

Volume47.38K

Average Volume (3M)133.41K

Market Cap

kr204.67M

Enterprise Valuekr129.76M

Total Cash (Recent Filing)kr19.90M

Total Debt (Recent Filing)kr7.56M

Price to Earnings (P/E)―

Beta0.60

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding68,452,890

10 Day Avg. Volume157,519

30 Day Avg. Volume133,406

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.31

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.31

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Clinical PipelineA concentrated pipeline in sexual and reproductive health with small-molecule candidates signals strategic focus and domain expertise. That specialization can improve R&D efficiency, foster regulatory know-how, and make assets more attractive to partners for late-stage development and commercialization over the coming months.

Low Financial LeverageVery low debt relative to equity provides financial flexibility for a pre-revenue biotech, reducing near-term insolvency risk and preserving options to manage financing timing. Modest leverage supports runway extension choices such as partnering or structured financings without excessive interest burden.

Improving Free Cash Flow RelationAn improved free cash flow ratio versus the prior year indicates incremental efficiency in cash use despite negative levels. While still negative, the narrower gap between FCF and net loss suggests spending is becoming relatively more cash-conservative, aiding runway management and partner negotiations over the medium term.

Bears Say

Pre-revenue With Widening LossesThe company remains pre-revenue with materially widening losses year-over-year, reflecting sustained R&D and operating spend without commercial offsets. This structural loss profile means ongoing dependence on external financing and creates execution risk if clinical progress or partner deals are delayed.

Declining Equity / Dilution RiskA substantial drop in equity over a short period signals cumulative losses and potential dilution if the company raises capital. Reduced book equity weakens the balance sheet buffer, increasing the likelihood of future equity issuance that could dilute existing holders and affect long-term capital structure.

Very Small Internal TeamA two-person headcount implies heavy reliance on external CROs, consultants, and partners for clinical development and operations. While cost-efficient, such a minimal internal team can limit oversight, slow decision cycles, and heighten execution and coordination risk in complex trials and regulatory interactions.

INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?

Initiator Pharma A/S lowest stock price was kr2.56 and its highest was kr4.17 in the past 12 months.

What is Initiator Pharma A/S’s market cap?

Initiator Pharma A/S’s market cap is kr204.67M.

When is Initiator Pharma A/S’s upcoming earnings report date?

Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 90 days.

How were Initiator Pharma A/S’s earnings last quarter?

Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.

Is Initiator Pharma A/S overvalued?

According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Initiator Pharma A/S pay dividends?

Initiator Pharma A/S does not currently pay dividends.

What is Initiator Pharma A/S’s EPS estimate?

Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Initiator Pharma A/S have?

Initiator Pharma A/S has 68,452,890 shares outstanding.

What happened to Initiator Pharma A/S’s price movement after its last earnings report?

Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.

Which hedge fund is a major shareholder of Initiator Pharma A/S?

Currently, no hedge funds are holding shares in SE:INIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Initiator Pharma A/S

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.